atorvastatin has been researched along with Acute Confusional Senile Dementia in 41 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (34.15) | 29.6817 |
| 2010's | 21 (51.22) | 24.3611 |
| 2020's | 6 (14.63) | 2.80 |
| Authors | Studies |
|---|---|
| Becker, S; Giller, K; Griesinger, C; Karami, L; Moosavi-Movahedi, AA; Nedaei, H; Rezaei-Ghaleh, N; Saboury, AA | 1 |
| Ahmed, A; Cheng, Y; Shao, Y; Wu, WC; Zamrini, E; Zeng-Treitler, Q | 1 |
| Patel, A; Patel, B; Patel, M; Patel, S; Patel, V; Shah, A; Shah, U; Solanki, N | 1 |
| Bottiglieri, T; Fardo, DW; Johnson, SN; Qiao, Q; Rogers, CB; Sudduth, TL; Weekman, EM; Wilcock, DM; Xie, K | 1 |
| Chen, M; Collu, R; Daley, S; Giunti, E; Xia, W | 1 |
| Çelik, H; Karahan, H; Kelicen-Uğur, P | 1 |
| Corrigan, B; Hooker, AC; Ito, K; Karlsson, MO; Plan, EL; Ueckert, S | 1 |
| Bullock, R; Craig, D; Malouf, R; McGuinness, B; Passmore, P | 1 |
| Wan, Q; Zhao, L; Zhao, Q; Zhao, Y; Zhou, Y | 1 |
| Chen, L; Chen, T; Li, G; Wan, Q; Wang, C; Yin, J; Zhao, L; Zhi, W | 1 |
| Baxter, LC; Connor, DJ; Haut, MW; Johnson, SC; Lemieux, SK; Lopez, JE; Sabbagh, MH; Sampath, H; Sparks, DL; Sparks, LM | 1 |
| Breazna, A; Doody, R; Feldman, H; Hey-Hadavi, J; Jones, RW; Kivipelto, M; Ramos, H; Schindler, RJ; Sparks, L; Waters, DD | 1 |
| Sabbagh, MN | 1 |
| Alena, T; Brcakova, E; Cibicek, N; Cibickova, L; Daniel, J; Eva, B; Helena, Z; Hyspler, R; Jun, D; Micuda, S; Norbert, C; Palicka, V; Radomir, H; Stanislav, M; Ticha, A; Vladimir, P; Zivna, H | 1 |
| Baker, SP; Caselli, R; Evans, BA; Evans, JE; Hinerfeld, D; Kane, K; Moonis, M; Pollen, DA; Rogaeva, E; St George-Hyslop, P; Swearer, J | 1 |
| Arvanitakis, Z; Knopman, DS | 1 |
| Breazna, A; DeMicco, DA; Doody, RS; Feldman, HH; Hey-Hadavi, J; Jones, RW; Kivipelto, M; Schindler, R; Schwam, E; Sparks, DL; Waters, DD | 1 |
| Bullock, R; Craig, D; Malouf, R; McGuinness, B; O'Hare, J; Passmore, P | 1 |
| Abe, K; Ikeda, Y; Kozuki, M; Kurata, T; Matsuura, T; Miyazaki, K; Morimoto, N; Nagai, M; Ohta, Y; Panin, VL | 1 |
| Butterfield, DA | 1 |
| Barone, E; Butterfield, DA; Cenini, G; Di Domenico, F; Head, E; Mancuso, C; Martin, S; Murphy, MP; Sultana, R | 1 |
| Abe, K; Ikeda, Y; Kozuki, M; Kurata, T; Miyazaki, K; Morimoto, N; Ohta, Y | 3 |
| Barone, E; Butterfield, DA; Mancuso, C | 1 |
| Barone, E; Butterfield, DA; Cenini, G; Di Domenico, F; Head, E; Mancuso, C; Murphy, MP; Sultana, R | 1 |
| Barone, E; Butterfield, DA; Di Domenico, F; Head, E; Mancuso, C; Murphy, MP; Sultana, R | 1 |
| Schneider, A; Simons, M | 1 |
| Alsop, DC; Asthana, S; Barnet, JH; Blazel, HM; Carlsson, CM; Chappell, RJ; Fain, SB; Johnson, SC; Rowley, HA; Sager, MA; Stein, JH; Wen, Z; Xu, G | 1 |
| Abe, K; Ikeda, Y; Kawai, H; Kozuki, M; Kurata, T; Miyazaki, K; Morimoto, N; Ohta, Y | 1 |
| Abe, K; Ikeda, Y; Kawai, H; Kurata, T; Miyazaki, K; Morimoto, N; Ohta, Y | 1 |
| Fan, YC; Li, XH; Wang, D; Wang, M; Zhang, YY | 1 |
| Carter, TL; Ehrlich, ME; Gandy, S; Pedrini, S; Petanceska, S; Prendergast, G | 1 |
| Browne, P; Connor, DJ; Johnson-Traver, S; Launer, LJ; Lochhead, J; Lopez, J; Sabbagh, MN; Sparks, DL; Wasser, D; Ziolwolski, C | 1 |
| Browne, P; Connor, DJ; Johnson-Traver, S; Launer, LJ; Lochhead, J; Lopez, J; Petanceska, S; Sabbagh, MN; Sparks, DL; Wassar, D; Ziolkowski, C | 1 |
| Adler, C; Browne, P; Connor, D; Lochhead, J; Lopez, J; Petanceska, S; Sabbagh, M; Soares, H; Sparks, DL; Ziolkowski, C | 1 |
| Browne, P; Connor, DJ; Lopez, J; Petersen, RB; Sabbagh, MN; Sparks, DL | 1 |
| Sparks, DL; Stankovic, G | 1 |
| Wong, V | 1 |
| Bonetta, L | 1 |
5 review(s) available for atorvastatin and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
The calcium-free form of atorvastatin inhibits amyloid-β(1-42) aggregation in vitro.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Animals; Atorvastatin; Calcium; Humans; Mice; Peptide Fragments | 2022 |
Atorvastatin's Reduction of Alzheimer's Disease and Possible Alteration of Cognitive Function in Midlife as well as its Treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Atorvastatin; Cognition; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; tau Proteins | 2023 |
Statins for the treatment of dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Atorvastatin; Dementia; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2014 |
Statins for the treatment of dementia.
Topics: Alzheimer Disease; Atorvastatin; Dementia; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2010 |
Atorvastatin and Aβ(1-40): not as simple as cholesterol reduction in brain and relevance to Alzheimer disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Atorvastatin; Brain; Cholesterol; Heptanoic Acids; Humans; Peptide Fragments; Pyrroles | 2011 |
9 trial(s) available for atorvastatin and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Atorvastatin May Correct Dyslipidemia in Adult Patients at Risk for Alzheimer's Disease Through an Anti-Inflammatory Pathway.
Topics: Adult; Alzheimer Disease; Anti-Inflammatory Agents; Anticholesteremic Agents; Atorvastatin; Dyslipidemias; Female; Humans; Inflammation Mediators; Male; Middle Aged; Risk Factors | 2016 |
The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anticholesteremic Agents; Atorvastatin; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Indans; Lipids; Male; Middle Aged; Piperidines; Pyrroles | 2008 |
Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Atorvastatin; Cholesterol, LDL; Cholinergic Antagonists; Double-Blind Method; Female; Heptanoic Acids; Hippocampus; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Imaging; Male; Middle Aged; Organ Size; Pyrroles | 2010 |
Effects of atorvastatin on cerebral blood flow in middle-aged adults at risk for Alzheimer's disease: a pilot study.
Topics: Adult; Aged; Alzheimer Disease; Atorvastatin; Cerebrovascular Circulation; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pilot Projects; Pyrroles; Risk Factors | 2012 |
Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anticholesteremic Agents; Atorvastatin; Cholesterol; Double-Blind Method; Female; Heptanoic Acids; Humans; Male; Mental Status Schedule; Neuropsychological Tests; Placebos; Pyrroles; Treatment Outcome | 2005 |
Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cognition; Depression; Disease Progression; Double-Blind Method; Female; Free Radicals; Heptanoic Acids; Humans; Male; Mental Status Schedule; Pilot Projects; Pyrroles; Severity of Illness Index; Time Factors; Treatment Outcome | 2005 |
Cholesterol, copper and Abeta in controls, MCI, AD and the AD cholesterol-lowering treatment trial (ADCLT).
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Atorvastatin; Ceruloplasmin; Cholesterol; Cholinergic Antagonists; Cognition Disorders; Copper; Cross-Sectional Studies; Heptanoic Acids; Humans; Longitudinal Studies; Middle Aged; Peptide Fragments; Pyrroles; Verbal Learning | 2005 |
Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Apolipoproteins E; Atorvastatin; Cholesterol; Cognition Disorders; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Neuropsychological Tests; Pyrroles; Severity of Illness Index; Treatment Outcome | 2006 |
Change in circulating C-reactive protein is not associated with atorvastatin treatment in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cognition; Coronary Artery Disease; Heptanoic Acids; Humans; Middle Aged; Neuropsychological Tests; Placebos; Prognosis; Pyrroles; Vasculitis | 2006 |
27 other study(ies) available for atorvastatin and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Medication-Wide Association Study Plus (MWAS+): A Proof of Concept Study on Drug Repurposing.
Topics: Alzheimer Disease; Atorvastatin; Drug Repositioning; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Proof of Concept Study; Prospective Studies | 2022 |
Atorvastatin rescues hyperhomocysteinemia-induced cognitive deficits and neuroinflammatory gene changes.
Topics: Alzheimer Disease; Animals; Atorvastatin; Cognition; Cognitive Dysfunction; Dementia, Vascular; Homocysteine; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperhomocysteinemia; Mice | 2023 |
Angiotensin-converting enzyme inhibitors and statins therapies-induced changes in omics profiles in humans and transgenic tau mice.
Topics: Alzheimer Disease; Angiotensin-Converting Enzyme Inhibitors; Animals; Atorvastatin; Disease Models, Animal; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lisinopril; Mice; Mice, Transgenic; Proteomics; tau Proteins | 2023 |
Effect of atorvastatin on Aβ
Topics: Alzheimer Disease; Aminopeptidases; Amyloid beta-Peptides; Apoptosis; Atorvastatin; Autophagy; Cell Line, Tumor; Cell Survival; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Humans; Microtubule-Associated Proteins; Neuroblastoma; Neuroprotection; Neuroprotective Agents; Nuclear Proteins; Peptide Fragments; Serine Proteases; Sirtuin 1; Tripeptidyl-Peptidase 1 | 2020 |
Improved utilization of ADAS-cog assessment data through item response theory based pharmacometric modeling.
Topics: Alzheimer Disease; Atorvastatin; Clinical Trials, Phase III as Topic; Cognition Disorders; Databases, Factual; Heptanoic Acids; Humans; Longitudinal Studies; Models, Biological; Pyrroles; Statistics as Topic | 2014 |
Atorvastatin in improvement of cognitive impairments caused by amyloid β in mice: involvement of inflammatory reaction.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Atorvastatin; Cytokines; Disease Models, Animal; Hippocampus; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Long-Term Potentiation; Maze Learning; Mice, Inbred C57BL | 2016 |
Hippocampal volume change in the Alzheimer Disease Cholesterol-Lowering Treatment trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anticholesteremic Agents; Atorvastatin; Cognition; Diagnostic Techniques, Neurological; Female; Heptanoic Acids; Hippocampus; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Pilot Projects; Psychological Tests; Psychophysiology; Pyrroles; Risk Factors | 2008 |
Commentary on "the Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics".
Topics: Alzheimer Disease; Anticholesteremic Agents; Atorvastatin; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Heptanoic Acids; Humans; Indans; Multicenter Studies as Topic; Piperidines; Pyrroles; Randomized Controlled Trials as Topic | 2008 |
The influence of simvastatin, atorvastatin and high-cholesterol diet on acetylcholinesterase activity, amyloid beta and cholesterol synthesis in rat brain.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Anticholesteremic Agents; Atorvastatin; Brain; Brain Chemistry; Cholesterol; Cholesterol, Dietary; Diet; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Male; Pyrroles; Rats; Rats, Wistar; Simvastatin | 2009 |
Long-term statin therapy and CSF cholesterol levels: implications for Alzheimer's disease.
Topics: Adult; Aged; Alzheimer Disease; Apolipoproteins E; Atorvastatin; Cholesterol; Female; Heptanoic Acids; Heterozygote; Humans; Hydroxycholesterols; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Mutation; Pilot Projects; Presenilin-1; Pyrroles; Simvastatin | 2009 |
Clinical trial efforts in Alzheimer disease: why test statins?
Topics: Alzheimer Disease; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Randomized Controlled Trials as Topic | 2010 |
Atorvastatin and pitavastatin improve cognitive function and reduce senile plaque and phosphorylated tau in aged APP mice.
Topics: Aging; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Atorvastatin; Body Weight; Brain; Cognition Disorders; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Maze Learning; Mice; Mice, Transgenic; Neuroprotective Agents; Organ Size; Phosphorylation; Plaque, Amyloid; Protein Processing, Post-Translational; Pyrroles; Quinolines; tau Proteins | 2011 |
Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: a novel mechanism of action.
Topics: Alzheimer Disease; Animals; Antioxidants; Atorvastatin; Brain; Cholesterol; Disease Models, Animal; Dogs; Female; Heptanoic Acids; Male; Nitroso Compounds; Oxidative Stress; Pyrroles; Random Allocation | 2011 |
Atorvastatin and pitavastatin protect cerebellar Purkinje cells in AD model mice and preserve the cytokines MCP-1 and TNF-α.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Atorvastatin; Chemokine CCL2; Disease Models, Animal; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Mice; Mice, Transgenic; Purkinje Cells; Pyrroles; Quinolines; Tumor Necrosis Factor-alpha | 2011 |
Cholesterol-independent neuroprotective and neurotoxic activities of statins: perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disorders.
Topics: Alzheimer Disease; Animals; Atorvastatin; Cholesterol; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Neurodegenerative Diseases; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides | 2011 |
Atorvastatin treatment in a dog preclinical model of Alzheimer's disease leads to up-regulation of haem oxygenase-1 and is associated with reduced oxidative stress in brain.
Topics: Aldehydes; Alzheimer Disease; Animals; Anticholesteremic Agents; Atorvastatin; Brain; Cognition Disorders; Disease Models, Animal; Dogs; Glutathione; Heme Oxygenase-1; Heptanoic Acids; Ketocholesterols; Linear Models; Liver; Oxidative Stress; Pyrroles; Up-Regulation | 2012 |
Progressive neurovascular disturbances in the cerebral cortex of Alzheimer's disease-model mice: protection by atorvastatin and pitavastatin.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Atorvastatin; Blotting, Western; Cerebral Cortex; Cerebrovascular Circulation; Disease Models, Animal; Endothelium, Vascular; Enzyme Activation; Female; Fluorescent Antibody Technique; Heptanoic Acids; Humans; Immunohistochemistry; Matrix Metalloproteinase 9; Mice; Mice, Transgenic; Neuroprotective Agents; Pyrroles; Quinolines | 2011 |
Biliverdin reductase-A: a novel drug target for atorvastatin in a dog pre-clinical model of Alzheimer disease.
Topics: Alzheimer Disease; Animals; Atorvastatin; Biomarkers; Blotting, Western; Brain; Cerebellum; Cognition; Dogs; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoprecipitation; Learning; Liver; Neuroprotective Agents; Oxidative Stress; Oxidoreductases Acting on CH-CH Group Donors; Parietal Lobe; Phosphorylation; Protein Processing, Post-Translational; Pyrroles; Up-Regulation | 2012 |
Antioxidative strategies in cognitive impairment: a novel connection between biliverdin-reductase and statins.
Topics: Alzheimer Disease; Animals; Atorvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neuroprotective Agents; Oxidoreductases Acting on CH-CH Group Donors; Pyrroles | 2012 |
Atorvastatin and pitavastatin reduce senile plaques and inflammatory responses in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Atorvastatin; Brain; Disease Models, Animal; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Inflammation; Mice; Mice, Transgenic; Plaque, Amyloid; Pyrroles; Quinolines | 2012 |
Statins have therapeutic potential for the treatment of Alzheimer's disease, likely via protection of the neurovascular unit in the AD brain.
Topics: Age Factors; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol; Collagen Type IV; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Glial Fibrillary Acidic Protein; Glucosamine; Heptanoic Acids; Humans; Matrix Metalloproteinase 9; Maze Learning; Methylcellulose; Mice; Mice, Transgenic; Mutation; Pyrroles; Quinolines | 2012 |
Atorvastatin and pitavastatin reduce oxidative stress and improve IR/LDL-R signals in Alzheimer's disease.
Topics: Adiponectin; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Atorvastatin; Cerebral Cortex; Endothelium, Vascular; Female; Glycation End Products, Advanced; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leptin; Mice; Neurons; Oxidative Stress; Plaque, Amyloid; Pyrroles; Quinolines; Receptor, Insulin; Receptors, LDL | 2013 |
Atorvastatin attenuates the production of IL-1β, IL-6, and TNF-α in the hippocampus of an amyloid β1-42-induced rat model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anticholesteremic Agents; Atorvastatin; Disease Models, Animal; Heptanoic Acids; Hippocampus; Inflammation Mediators; Interleukin-1beta; Interleukin-6; Male; Pyrroles; Rats; Rats, Wistar; Tumor Necrosis Factor-alpha | 2013 |
Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK.
Topics: Alzheimer Disease; Amino Acid Sequence; Amyloid beta-Protein Precursor; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracellular Signaling Peptides and Proteins; Molecular Sequence Data; Neuroblastoma; Phosphorylation; Protein Serine-Threonine Kinases; Pyrroles; rho-Associated Kinases; Simvastatin; Tumor Cells, Cultured | 2005 |
Cholesterol drug may help treat Alzheimer's.
Topics: Alzheimer Disease; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2005 |
Medication use as a confounding factor in the use of the cerebrospinal fluid tau/beta-amyloid42 ratio.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Biomarkers; Cyclooxygenase Inhibitors; Estrogens; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Peptide Fragments; Pyrroles; tau Proteins | 2007 |
Potential neurological value of statins increases.
Topics: Alzheimer Disease; Anticholesteremic Agents; Atorvastatin; Costs and Cost Analysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Nervous System Diseases; Pyrroles; United States | 2002 |